Peucedanocoumarin III
Based on 1 Customer Validation
Peucedanocoumarin III is an α-synuclein fiber depolymerizer with blood-brain barrier permeability. Peucedanocoumarin III depolymerizes β-sheet aggregate structures, promotes aggregate clearance, inhibits β23-induced cytotoxicity, blocks the formation of Lewy body-like inclusions, and prevents dopaminergic neuron loss. Peucedanocoumarin III can be used in studies related to Parkinson's disease.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 95.07%
- CAS No.: 130464-57-2
- Formule: C21H22O7
- Masse moléculaire:386.40
-
Stockage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform α-synuclein
More
Activité biologique
|
α-synuclein Aggregation |
Purified and synthetic Peucedanocoumarin III (1 µM; 37-48 h) similarly clear β23 aggregates and protect SH-SY5Y cells from β23-induced toxicity[1].
Synthetic Peucedanocoumarin III partially protects protects HA-α-synuclein-transfected SH-SY5Y cells from 6-OHDA-induced cytotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| Species | Dose | Route | Brain Concentration |
|---|---|---|---|
| Mice[1] | 10 mg/kg | i.p. | 230 ng/g |
Peucedanocoumarin III (10 mg/kg/day; i.p.; daily; 7 days) is well-tolerated in healthy mice, shows no adverse effects on body weight, motor function, or tissue structure, and penetrates the blood-brain barrier to reach therapeutic target tissue[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6N (male, 2 months old, intrastriatal stereotaxic injection of 6-OHDA)[1]
-
Dosage:1 mg/kg/day
-
Administration:i.p.; daily; 7 days
-
Result:Substantially reduced phospho-serine 129 α-synuclein (pS129-α-Syn) positive Lewy-like inclusion intensities.
Largely alleviated 6-OHDA-induced dopaminergic neuron loss in the substantia nigra pars compacta.
Substantially protected against 6-OHDA-induced loss of striatal dopaminergic nerve terminals.
Reduced 6-OHDA-induced GFAP immunofluorescence signal increase by about two-fold relative to PBS controls.
-
Animal Model:C57BL/6N (male, 2 months old)[1]
-
Dosage:10 mg/kg/day
-
Administration:i.p.; daily; 7 days
-
Result:Showed no statistically significant difference in body weight relative to DMSO controls.
Showed no statistically significant differences in total open field exploration distance, time/distance spent in arena zones, rotarod latency/speed, or pole test time to ground relative to DMSO controls.
Distributed to all tested tissues, with brain levels of 230 ng/g tissue, heart levels of 231 ng/g tissue, lung levels of 121 ng/g tissue, liver levels of 105 ng/g tissue, kidney levels of 162 ng/g tissue, and spleen levels of 109 ng/g tissue.
Showed no structural abnormalities in heart, lung, liver, kidney, or spleen via H&E staining.
Showed no statistically significant difference in GFAP immunofluorescence signal in cortex, hippocampus, striatum, or ventral midbrain relative to DMSO controls.
Chemical Information
-
CAS No. 130464-57-2
-
Appearance Solid
-
Masse moléculaire 386.40
-
Formule C21H22O7
-
Color White to off-white
-
SMILES
C/C=C(C)/C(O[C@@H]1C2=C(OC(C)([C@H]1OC(C)=O)C)C=CC(C=C3)=C2OC3=O)=O
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ham S, et al. Therapeutic Evaluation of Synthetic Peucedanocoumarin III in an Animal Model of Parkinson's Disease. Int J Mol Sci. 2019;20(21):5481. Published 2019 Nov 4. [Content Brief]
[2]. Jiang J, et al. Growth Year and Chemotype Synergistically Regulate Coumarin Accumulation and the Associated Transcriptional Profiles in Peucedanum praeruptorum Dunn. Plants (Basel). 2026 Feb 13;15(4):598. [Content Brief]
[3]. Chen IS, et al. Coumarins and antiplatelet aggregation constituents from Formosan Peucedanum japonicum. Phytochemistry. 1996;41(2):525-530. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Peucedanocoumarin III Related Classifications
HY-122958 Related Classifications
Powered by Bioz